demonstrated the benefits of intensive glycemic control on the long-term microvascular and neurologic complications of type 1 diabetes mellitus (1) (2) (3) (4) (5) . Essential to this decade-long study was the availability of a consistent, reliable hemoglobin A 1c (HbA 1c ) assay (6 ) . In addition, the follow-up study of the DCCT, the Epidemiology of Diabetes Interventions and Complications (EDIC), now in its 10th year, required similarly consistent HbA 1c results that could be compared with the DCCT results (7, 8 ) . With three changes in the methodology for HbA 1c , sustaining comparable values continuously during the 20 years of the DCCT and EDIC has presented a major challenge. In this communication we describe the measures taken to assure consistency of the HbA 1c results over two decades of study.
The DCCT enrolled 1441 individuals with type 1 diabetes mellitus, beginning in 1983 (9 ) . Although the DCCT ended in 1993 (1 ) , EDIC, the follow-up study, continues to the present. To sustain the consistency of the HbA 1c values over the combined duration of these studies, the assay systems used to measure HbA 1c have been calibrated and monitored against a single reference procedure (6 ) . Together these assays defined a consistent nondiabetic range (4.0 -6.05%) over the course of the DCCT (1 ) and EDIC. Furthermore, the outcomes of these studies set the basis of the HbA 1c treatment goal (7%) recommended by the American Diabetes Association (10 ) .
laboratories
The Central Hemoglobin Laboratory (CHL) and Backup Hemoglobin Laboratory (BHL) were established in 1983. The CHLs have analyzed all routine HbA 1c specimens for the DCCT and EDIC. The BHL has provided external quality control (QC) and backup laboratory services for the CHL. The CHL was initially located at the Joslin Diabetes Center (Boston, MA); the BHL has been continuously located at the University of Missouri-Columbia School of Medicine (6 ) . In 1986, all measurements of HbA 1c were temporarily moved to the BHL for 6 months, until the CHL was moved to the University of Minnesota (Minneapolis, MN). New instruments with automated capacity [initially Diamat HPLC (Bio-Rad Laboratories) and subsequently Tosoh A1c 2.2 Plus HPLC (Tosoh Medics, Inc.)] were introduced in Minnesota. For all CHL assays, calibrators were assigned values based on comparisons between the CHL and the BHL (see below). Separate QC aliquots were assayed in the CHLs to determine acceptance of each assay run.
reference method at the bhl
The BHL has performed the reference method for HbA 1c during the entire course of the DCCT and EDIC, using a HPLC assay with Bio-Rex 70 ion-exchange resin, as described in detail previously (6 ) . Whole blood was transported at 4°C on wet ice by overnight courier from clinical centers to the BHL. The labile glycated fraction was removed by incubation of washed, packed erythrocytes in saline at 37°C for at least 5 h, with subsequent lysis of the erythrocytes in water. Cellular debris was removed by mixing with CCl 4 followed by centrifugation; the hemolysate sample was injected on the HPLC column. (6 ) . The hemolysate preparation was similar to that prepared at the BHL. In addition to the long-term (QC) sample, the Joslin CHL also prepared low, medium, and high pooled controls, which were used at both Joslin and the BHL between 1983 and 1987. The BHL then prepared additional control materials, using single diabetic and nondiabetic donors; these control materials were used from 1987 to present.
first chl method
The first CHL, based at the Joslin Diabetes Center, used a HPLC method identical to the method used at the BHL until early 1986, with calibration and internal QC procedures as described previously (6 ) .
second chl method
Based at the University of Minnesota (Minneapolis, MN), a Diamat HPLC dedicated ion-exchange system was used from November 1986 until April 2002 (1 ). The Diamat instrument was calibrated daily by use of a single calibrator provided by the manufacturer (with a value of 8 -9%) standardized to the BHL reference system. Nominal values for this calibrator were adjusted based on comparisons between the CHL and BHL for the samples assayed in both the CHL and BHL. With each new lot of calibrator, values were checked and adjusted based on analysis with the previous calibrator. Occasionally (e.g., with changes in columns at the CHL), in-house whole-blood materials were exchanged between the CHL and BHL to verify CHL calibration. These comparisons were in addition to the QC specimens used by the CHL to monitor the assay with each run and to accept or reject the run. During the DCCT and EDIC, different lots of columns and reagents were provided by Bio-Rad, some with apparently different performance characteristics; these are noted when appropriate.
third chl method
In April 2002, a Tosoh A1c 2.2 Plus dedicated ionexchange HPLC system replaced the Diamat system at the CHL. The Tosoh 2.2 Plus was calibrated weekly by use of two calibrators provided by the manufacturer (usually with values of ϳ5% and 11% for each calibrator), with values adjusted based on comparisons with the BHL and with consistency checked as described above for the Diamat. All data reduction was performed automatically; analysis time was 3 min. The transition from the Diamat to the Tosoh instrument was monitored with 178 samples, showing consistency (r 2 ϭ 0.992; y ϭ 1.036x Ϫ 0.236, where x is the Diamat and y is the Tosoh 2.2 Plus) between the instruments.
external qc for chl analyses
For external QC throughout the DCCT, ϳ10% of the specimens were prepared as split duplicates at the clinical centers; samples were sent masked to the BHL and CHL (1 ). On a quarterly basis, some centers shipped additional split-duplicate specimens to both the CHL and BHL. After 1993, 10 samples were exchanged monthly between the CHL and BHL. Beginning in May 1996, this monthly 10-sample exchange became part of the National Glycohemoglobin Standardization Program (NGSP) network monitoring program. Differences between the BHL and CHL were used as needed to recalibrate the assays in the CHL, as described above. In addition, 5-10% of specimens were split and sent as duplicates, to check on reliability of the system from collection through shipping, analysis in the laboratory, and reporting to the Biostatistics Center at George Washington University.
reproducibility of the nondiabetic range
As an additional check to ensure that the HbA 1c assay did not drift over the course of the DCCT and EDIC studies, four nondiabetic range studies were performed with the assumption that the true nondiabetic range should not change over time (1 ) . The first study was performed in 1983 at the onset of the DCCT; the second study in 1988 after the CHL changed from Joslin to Minnesota; the third study in 1992 at the end of the DCCT; and the fourth study in 2000, during EDIC. For each study in 1983, 1985, and 1992, nondiabetic individuals were enrolled, selected to match the age and gender distributions of the DCCT/ EDIC groups at baseline; in 2000, the age and gender distribution matched the contemporary age of the EDIC participants. Thus, the nondiabetic individuals in 2000 were older than the previously measured nondiabetic groups. All were recruited from all participating clinical sites in the United States and Canada. Before 2000, local glucose values were used to assure nondiabetic status. For the 2000 study, fasting glucose was measured centrally with a glucose oxidase method [on a Vitros analyzer (Ortho Clinical Diagnostics)] at the CHL to assure that no participants had impaired fasting glucose or diabetes mellitus. HbA 1c was analyzed by both the CHL and BHL.
statistical analyses
Values are reported as the mean (SD). The coefficient of reliability was determined as: (between-specimen variance Ϫ within-specimen variance)/(between-specimen variance ϩ within-specimen variance) (11, 12 ) 
Results

stability of a reference method for two decades
Yearly means for a very long term lot of frozen hemolysate used for nearly two decades as a QC specimen by the BHL are shown in Fig. 1 . Thus, we relied on the other control samples to demonstrate the consistency of the assay, with the overlapping lots demonstrating equally good stability over time (Fig. 1) .
The nondiabetic range studies, postulated to demonstrate no changes in mean values in a healthy nondiabetic population over time, also confirmed the stability of the assay and the frozen hemolysates used for QC. The values of HbA 1c and selected characteristics of the nondiabetic populations over the course of the DCCT and EDIC are shown in Table 1 . There were no appreciable differences Table 1 The split duplicate samples (i.e., aliquots of the same collection) sent separately to the CHLs showed consistency, with a coefficient of reliability Ͼ0.99 spanning the 20 years of the DCCT/EDIC. Overall HbA 1c values in the CHL vs the BHL differed slightly throughout the DCCT and for most of EDIC. However, despite efforts to sustain similar values, there were small differences between the CHL Diamat and the BHL, especially in the high HbA 1c concentration range (Ͼ10% HbA 1c ), which increased beginning in 1995 until the CHL Diamat was replaced by the Tosoh 2.2 Plus in 2002. We addressed the timing (and the possible causes) for the differences between the methods that occurred during EDIC by examining the differences over time and within each lot of columns and reagents supplied by Bio-Rad, believing that most of the differences occurred with changes in columns and reagents. In doing so we found that the performance of column Lot M (which was used in the laboratory March 1993 to July 1996) deteriorated over the last half of its life (data not shown). To determine the relative magnitude of the differences post-DCCT, we used the mean values of the differences from 1987 to mid-1993 (covering the performance of the Diamat during the DCCT) as the baseline. We then subtracted the 1987-1993 values from each of the mean values in EDIC, with the results presented in Fig. 2 . Only for HbA 1c values Ͼ10% were the absolute differences in mean values Ͼ0.2%.
In April 2002, the Tosoh A1c 2.2 Plus replaced the Bio-Rad Diamat in the CHL. The performance of the method was similar to the performance of the Diamat method during the DCCT (1987 DCCT ( -1993 at HbA 1c concentrations Ͻ10% and was only slightly higher (0.2%) in the Ͼ10% HbA 1c range (Fig. 2) .
Discussion
The DCCT/EDIC Study and the United Kingdom Prospective Diabetes Study (UKPDS) have shown that intensive treatment of diabetes mellitus, aiming for normoglycemia, decreases the development and/or progression of long-term complications in type 1 and type 2 diabetes mellitus, respectively (1, 8, (13) (14) (15) . Both the DCCT and UKPDS have also shown a strong correlation between HbA 1c concentrations and complications (16, 17 ) . The conclusions of these studies rest on long-term consistency of the HbA 1c methods; i.e., the assays delineated in this report. Many other studies and clinical trials have used HbA 1c to measure long-term glycemic control [see Krishnamurti and Steffes (18 ) for a review of these studies]. In the UKPDS, Cull et al. (19 ) developed protocols to maintain consistency of their HbA 1c assay, similar to the DCCT/EDIC experience. The UKPDS used a Diamat assay (19 ) identical to that used for the greater part of the DCCT and EDIC.
By maintaining the same assay method over time at the BHL, we were able to monitor and achieve consistent a The data designated as years of age represent subsets (for which we have at least 30 participants) of the overall data presented as "All participants". (8, 15, 20 ) . The challenge of maintaining consistent values over two decades was compounded by the absence of a true standard for the assay. We were not able to precisely match the values from the CHL and BHL. The Diamat with single-point calibration was suboptimal in maintaining consistent values between the CHL and BHL at higher HbA 1c concentrations in both the DCCT and EDIC. The Tosoh A1c 2.2 Plus method also demonstrated somewhat greater variance with the BHL at the highest HbA 1c concentrations, although to a lesser degree than the Diamat, possibly because of the two-point calibration of the 2.2 Plus. Whether some of these differences may relate to properties of the Bio-Rex resin used in the BHL method and/or to the single-point calibration of the Bio-Rex assay is not clear. IN addition, the values of calibrators may not have been optimal to produce accurate values in the high ranges. Thus, even with the consistent exchange of samples between the BHL and the CHL, at higher HbA 1c concentrations, the differences between the methods increased during the last years of Diamat use. Perhaps this was attributable to the Diamat calibrators having values of ϳ8%, below the values where the BHL and CHL differed to the greatest extent. However, it should be noted that only 12% of DCCT patients and 7.5% of EDIC patients had HbA 1c concentrations Ͼ10%. Thus, there was little impact on the conclusions from these studies over nearly two decades of the DCCT and EDIC, despite changes in HbA 1c methodology.
The success of the NGSP in standardizing HbA 1c testing over the past several years (21 ) should allow continued consistency in results over time in many laboratories. This will facilitate prospective studies of relationships between glycemia and complications and ensure comparability among studies. It will also ensure optimal use of HbA 1c as a tool in patient care, especially with the American Diabetes Association stating a target value of 7% using methods traceable to DCCT values (10 ) . New reference procedures have been proposed (22 ) , and these may be used in conjunction with the NGSP to base the HbA 1c assays on definitive standards and methods. In addition, methods continue to improve with regard to precision and specificity. For these reasons, we expect that variation of results over time and among laboratories will progressively diminish, thereby providing even more consistency of HbA 1c results.
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